Aptamer-Modified Nanodrug Delivery Systems
Source abstract
Abstract
Aptamers can bind a wide range of biomedically relevant proteins with affinities and specificities that have therapeutic utility. Although aptamers are susceptible to nuclease-mediated degradation and cannot easily cross biological barriers, specific aptamer modification can feasibly solve these problems. To address these obstacles, Lau et al. developed a general strategy for generating natural packaging and transport vehicles for targeting agents, such as aptamers and their small-molecule ligands, by using virus-like particles (VLPs) assembled from the recombinant expression of the bacteriophage Qβ coat protein. Since RNA and DNA molecules are susceptible to nuclease-mediated degradation, it is important that Qβ VLPs protect their encapsulated aptamers from nuclease-mediated degradation and enhance their permeability. Moreover, if self-assembled using natural proteins, VLPs can guarantee the biocompatibility and biodegradability of modified aptamers in therapeutic applications. Therefore, this Perspective explores the outlook for such aptamer modification strategies for nanodrug preparation and delivery applications and the challenges that lie ahead.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Bacteriophages and microbial interactions · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Research at Bio/nano Interface, Department of Chemistry and Shands Cancer Center, University of Florida, Gainesville, Florida 32611, United States, and State Key Laboratory for Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, People’s Republic of China
References (22)
Show source-provided references
1. Keefe A. D. · Nat. Rev. Drug Discovery · 2010 · 9 · 53710.1038/nrd3141 ↗
2. Tuerk C. · Science · 1990 · 249 · 50510.1126/science.2200121 ↗
3. Ellington A. D. · Nature · 1990 · 346 · 81810.1038/346818a0 ↗
4. Griffin L. C. · Blood · 1993 · 81 · 327110.1182/blood.V81.12.3271.3271 ↗
5. Ng E. W. M. · Nat. Rev. Drug Discovery · 2006 · 5 · 12310.1038/nrd1955 ↗
6. Wu Y. R. · ACS Nano · 2008 · 2 · 202310.1021/nn800325a ↗
7. Bagalkot V. S. · Nano Lett. · 2007 · 7 · 306510.1021/nl071546n ↗
8. Kim D. K. · ACS Nano · 2010 · 4 · 368910.1021/nn901877h ↗
9. Chen L. Q. · J. Phys. Chem. B · 2010 · 114 · 365510.1021/jp9104618 ↗
10. He X. X. · Nanoscale · 2011 · 3 · 293610.1039/c0nr00913j ↗
11. Kim Y. G. · Proc. Natl. Acad. Sci. U.S.A. · 2008 · 105 · 566410.1073/pnas.0711803105 ↗
12. MaHam A. H. · Small · 2009 · 5 · 170610.1002/smll.200801602 ↗
13. Lewis J. D. · Nat. Med. · 2006 · 12 · 35410.1038/nm1368 ↗
14. Wang Q. · Bioconjugate Chem. · 2003 · 14 · 3810.1021/bc025587g ↗
15. Uchida M. · J. Am. Chem. Soc. · 2006 · 128 · 1662610.1021/ja0655690 ↗
16. Aime S. · Angew. Chem., Int. Ed. · 2002 · 41 · 101710.1002/1521-3773(20020315)41:6<1017::AID-ANIE1017>3.0.CO;2-P ↗
17. Lee T. K. · Science · 1981 · 213 · 23310.1126/science.6787705 ↗
18. Kratz F. · J. Controlled Release · 2008 · 132 · 17110.1016/j.jconrel.2008.05.010 ↗
19. Metzmacher I. · Eur. J. Pharm. Biopharm. · 2007 · 67 · 34910.1016/j.ejpb.2007.02.013 ↗
20. 10.1021/nn200692710.1021/nn2006927 ↗
21. Green N. K. · Gene Ther. · 2004 · 11 · 125610.1038/sj.gt.3302295 ↗
22. Schiedner G. · 2002 · 42910.1016/B978-012199504-1/50016-X ↗